Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study
European Journal of Neurology · 2026-03 · 33 (3)
DOI: 10.1111/ene.70569 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 13.03.2026. Verfasst von Dingxian He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fuda…. Hauptthemen laut MEDLINE: Myasthenia Gravis, Rituximab, Immunologic Factors. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Clinical Collaboration Project for Major and Difficult Diseases with Integrated Traditional Chinese and Western Medicine.
Abstract (Originalsprache)
Background
Optimal timing for treatment discontinuation in myasthenia gravis (MG) patients achieving minimal symptom expression (MSE) remains undefined.
Methods
This prospective cohort study enrolled 196 MG patients from the Huashan MG Registry who achieved MSE and subsequently discontinued all treatments. Cox regression was used to identify prognostic factors for relapse. Among these, 20 patients experienced two discontinuation events and were analyzed separately for their second discontinuation.
Results
Over a mean follow‐up of 111.10 months, 108 patients (55.1%) experienced relapse. Multivariate analysis identified four independent prognostic factors: onset age ≥ 50 years as a risk factor (HR 1.68, 95% CI 1.04–2.70, p = 0.032), and rituximab administration (HR 0.43, 95% CI 0.17–0.89, p = 0.015), treatment duration ≥ 14.3 months (HR 0.54, 95% CI 0.34–0.85, p = 0.008), and time from MSE to discontinuation ≥ 6.1 months (HR 0.51, 95% CI 0.32–0.83, p = 0.007) as protective factors. Infection, fatigue, and psychological stress were common relapse triggers.
Conclusions
Complete treatment discontinuation after MSE in MG carries substantial relapse risk. Individualized discontinuation decisions incorporating younger onset age, prior rituximab use, adequate treatment and consolidation duration may optimize outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.
- Department of Encephalopathy, The Affiliated Hospital to Changchun University of Chinese Medicine, Jilin, Changchun, China.
- Department of Neurology, Southern Central Hospital of Yunnan Province (The First People's Hospital of Honghe Prefecture), Gejiu, Yunnan, China.
ORCID-Profile: Sushan Luo, Chongbo Zhao
Förderung
- National Natural Science Foundation of China
- National Clinical Collaboration Project for Major and Difficult Diseases with Integrated Traditional Chinese and Western Medicine
Zitieren
APA
He, D., Yan, C., Wang, B., Yang, Y., Gu, S., Xi, J., Luo, S., & Zhao, C. (2026). Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study. European Journal of Neurology, 33(3). https://doi.org/10.1111/ene.70569
Vancouver
He D, Yan C, Wang B, Yang Y, Gu S, Xi J, et al. Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study. European Journal of Neurology. 2026;33(3). doi:10.1111/ene.70569
BibTeX
@article{He2026,
author = {He, Dingxian and Yan, Chong and Wang, Baitong and Yang, Yanlei and Gu, Shengying and Xi, Jianying and Luo, Sushan and Zhao, Chongbo},
title = {Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long‐Term Real‐World Study},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {3},
doi = {10.1111/ene.70569}
}
EUVIMED